Module 4: Novel Anticancer Agents and Their Clinical Implications
This learning activity has been designated for 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Upon completion of this education program the participant should be able to:
- Discuss the novel immunomodulatory agents and proteasome inhibitors recently approved for treatment of multiple myeloma;
- Cite and summarize pivotal clinical trial data concerning bortezomib, thalidomide, and lenalidomide;
- Describe the investigative efforts underway in evaluation of HSP90 inhibitors, Akt inhibitors, anti-CS1 monoclonal antibodies, anti–IL-6 monoclonal antibodies, and new proteasome inhibitors and immunomodulatory agents, as well as their potential role in combination with standard therapeutic agents for myeloma.
This learning activity is intended for medical oncologists, hematologists,
stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.
Release Date: December 31, 2008
Expiration date: December 31, 2009
(*Please check this box to proceed - required)
Start the Module